Tempus AI soars 40% in a week, adding $3.7 billion—over double the Personalis acquisition amount - TechStock²

Tempus AI, Inc. stock analysis reveals a sharp rally driven by acquisition, hitting overbought levels and signaling potential near-term volatility.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) has been assigned an average recommendation of "Hold" from the seventeen analysts that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy ratin

Three Tempus AI insiders -- diagnostics CEO Thomas Schoenherr, chief legal officer Andrew Polovin, and director Nadja West -- executed stock sales…

Personalis Inc. stocks have been trading up by 9.41 percent following highly positive sentiment from its most impactful recent news. What Traders Need To Know Q2 revenue came in at $22.4M, far above the $16.7M consensus, showing strong operating momentum into the Tempus AI deal. Clinical volume for the NeXT Personal MRD test surged 199%…

Tempus AI, Inc. has acquired Personalis' cancer monitoring tests to enhance its AI-driven precision medicine platform. This move aligns with recent cancer vaccine progress by Merck and Moderna, highlighting the strategic growth potential for Tempus. The company already benefits from higher test prices, and the acquisition could accelerate growth and increase market valuation multiples. Investors see this as a positive catalyst for Tempus' future performance.

This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.

Tempus AI stock has surged over the past month, yet the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to shares trading at a roughly 33.1% discount, while market based multiples lean expensive and the broader checks do not suggest a clear bargain. Tempus AI has returned about 54.8% over the past month, which puts extra focus on whether that jump is already pricing in much of the good news. The positive cancer vaccine trial linked to its planned...

This sale was non-discretionary, executed to cover tax withholding from RSU vesting.

These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.